Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Miyasaka, Aki ^a   Oda, Katsutoshi ^a   Ikeda, Yuji ^a   Wada Hiraike, Osamu ^a   Kashiyama, Tomoko ^a   Enomoto, Atsushi ^b   Hosoya, Noriko ^b   Koso, Takahiro ^a   Fukuda, Tomohiko ^a   Inaba, Kanako ^a   Sone, Kenbun ^a   Uehara, Yuriko ^a   Kurikawa, Reiko ^a   Nagasaka, Kazunori ^a   Matsumoto, Yoko ^a   Arimoto, Takahide ^a   Nakagawa, Shunsuke ^c   Kuramoto, Hiroyuki ^d   Miyagawa, Kiyoshi ^b   Yano, Tetsu ^e   Kawana, Kei ^a   Osuga, Yutaka ^a   Fujii, Tomoyuki ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d Kanagawa Health Service Association   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Endometrial cancer; Homologous recombination; PARP inhibitor; PTEN; RAD51

Indexed keywords

HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAD51 PROTEIN; SMALL INTERFERING RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOMETRIUM CANCER; GENE MUTATION; IONIZING RADIATION; PROTEIN EXPRESSION; RECOMBINATION REPAIR; ANTINEOPLASTIC ACTIVITY; CARCINOMA CELL; CARCINOMA CELL LINE; CELL SURVIVAL; CONCENTRATION (PARAMETERS); ENDOMETRIUM CARCINOMA; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MUTANT; POLYMERASE CHAIN REACTION; RADIATION EXPOSURE; WESTERN BLOTTING; WILD TYPE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; PHTHALAZINES; PIPERAZINES; PTEN PHOSPHOHYDROLASE; RAD51 RECOMBINASE; RADIATION, IONIZING;

EID: 84899088512     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-179     Document Type: Article

References (40)

1. Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature 1992, 356:356-358. 10.1038/356356a0, 1549180.
2. Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005, 70:139-148. 10.1101/sqb.2005.70.012, 16869747.
3. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011, 10:1192-1199. 10.4161/cc.10.8.15273, 3117132, 21487248.
4. Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P, Helleday T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 2009, 28:2601-2615. 10.1038/emboj.2009.206, 2738702, 19629035.
5. Yang YG, Cortes U, Patnaik S, Jasin M, Wang ZQ. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 2004, 23:3872-3882. 10.1038/sj.onc.1207491, 15021907.
6. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM, Matthews IT, Moore S, OConnor MJ, Smith GC, Martin NM. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem 2008, 51:6581-6591. 10.1021/jm8001263, 18800822.
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, OConnor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
8. Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011, 8:302-306. 10.1038/nrclinonc.2011.42, 21468130.
9. Williamson CT, Muzik H, Turhan AG, Zamo A, OConnor MJ, Bebb DG, Lees-Miller SP. ATM deficiency sensitizes mantle cell lymphoma cells to poly (ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010, 9:347-357. 10.1158/1535-7163.MCT-09-0872, 3729269, 20124459.
10. Min A, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, Kim HP, Lee KH, Han SW, Oh DY, Kim TY, OConnor MJ, Kim WH, Bang YJ. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol Cancer Ther 2013, 12:865-877. 10.1158/1535-7163.MCT-12-0950, 23512992.
11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
12. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005, 65:10669-10673. 10.1158/0008-5472.CAN-05-2620, 16322209.
13. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res 2008, 68:8127-8136. 10.1158/0008-5472.CAN-08-0755, 18829572.
14. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, Rice JM. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991, 51:5308-5314.
15. Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, Sone K, Miyamoto Y, Hiraike H, Hiraike-Wada O, Nei T, Kawana K, Kuramoto H, Aburatani H, Yano T, Taketani Y. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 2009, 101:145-148. 10.1038/sj.bjc.6605109, 2713716, 19491896.
16. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA, Das S. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001, 91:22-26. 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S, 11149415.
17. Toda T, Oku H, Khaskhely NM, Moromizato H, Ono I, Murata T. Analysis of microsatellite instability and loss of heterozygosity in uterine endometrial adenocarcinoma. Cancer Genet Cytogenet 2001, 126:120-127. 10.1016/S0165-4608(00)00400-3, 11376804.
18. Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 1995, 55:1922-1926.
19. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170. 10.1016/j.cell.2006.11.042, 17218262.
20. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, Piwnica-Worms H, Hibshoosh H, Parsons R. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005, 7:193-204. 10.1016/j.ccr.2005.01.009, 15710331.
21. Puc J, Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 2005, 4:927-929. 10.4161/cc.4.7.1795, 15970699.
22. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 2012, 18:1015-1027. 10.1158/1078-0432.CCR-11-2189, 3378487, 22114138.
23. Kuramoto H, Nishida M, Morisawa T, Hamano M, Hata H, Kato Y, Ohno E, Iida T. Establishment and characterization of human endometrial cancer cell lines. Ann N Y Acad Sci 1991, 622:402-421. 10.1111/j.1749-6632.1991.tb37884.x, 2064198.
24. Ikeda Y, Oda K, Nakagawa S, Murayama-Hosokawa S, Yamamoto S, Ishikawa S, Wang L, Takazawa Y, Maeda D, Wada-Hiraike O, Kawana K, Fukayama M, Aburatani H, Yano T, Kozuma S, Taketani Y. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. Int J Gynecol Cancer 2012, 22:725-731. 10.1097/IGC.0b013e31824c6ea6, 22635024.
25. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 2012, 7:e37431. 10.1371/journal.pone.0037431, 3360787, 22662154.
26. Tanikawa M, Wada-Hiraike O, Nakagawa S, Shirane A, Hiraike H, Koyama S, Miyamoto Y, Sone K, Tsuruga T, Nagasaka K, Matsumoto Y, Ikeda Y, Shoji K, Oda K, Fukuhara H, Nakagawa K, Kato S, Yano T, Taketani Y. Multifunctional transcription factor TFII-I is an activator of BRCA1 function. Br J Cancer 2011, 104:1349-1355. 10.1038/bjc.2011.75, 3078593, 21407215.
27. Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 2011, 13:442-449. 10.1007/s11912-011-0193-9, 21913063.
28. Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 2013, 288:367-374. 10.1007/s00404-013-2856-2, 23619942.
29. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly (ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012, 134:649-659. 10.1007/s10549-012-2106-5, 22678161.
30. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, Burma S. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly (ADP-ribose) polymerase inhibitors. Cancer Res 2010, 70:5457-5464. 10.1158/0008-5472.CAN-09-4295, 2896430, 20530668.
31. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho J. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010, 2:53ra75.
32. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 2008, 77:229-257. 10.1146/annurev.biochem.77.061306.125255, 18275380.
33. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322. 10.1002/emmm.200900041, 3378149, 20049735.
34. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868. 10.1074/jbc.273.10.5858, 9488723.
35. Sung P, Krejci L, Van Komen S, Sehorn MG. Rad51 recombinase and recombination mediators. J Biol Chem 2003, 278:42729-42732. 10.1074/jbc.R300027200, 12912992.
36. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, OConnor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006, 66:8109-8115. 10.1158/0008-5472.CAN-06-0140, 16912188.
37. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
38. Ward JF. The yield of DNA double-strand breaks produced intracellularly by ionizing radiation: a review. Int J Radiat Biol 1990, 57:1141-1150. 10.1080/09553009014551251, 1971840.
39. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M, Kiura K. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 2013, 11:140-148. 10.1158/1541-7786.MCR-12-0401, 23239809.
40. Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, Klein EA, Almasan A. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One 2013, 8:e60408. 10.1371/journal.pone.0060408, 3614551, 23565244.